TLP
XERS icon

Tri Locum Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Tri Locum Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,766
Closed -$49K – 87
2022
Q4 		$49K Buy
+36,766
New +$51.9K 0.02% 56

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Tri Locum Partners's XERS Position: Q1 2023 in Review

Tri Locum Partners sold out of Xeris Biopharma Holdings (XERS) in Q1 2023, closing a stake of 36,766 shares — an estimated $49K sold.

Tri Locum Partners first reported a position in XERS in Q4 2022 and held it in 1 quarter. The position peaked at $49K in Q4 2022. 92 funds tracked by Wall St. Rank hold XERS as of Q1 2023.

  • Tri Locum Partners reported no remaining Xeris Biopharma Holdings position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 36,766 Xeris Biopharma Holdings shares in Q1 2023, an estimated $49K.
  • Tri Locum Partners first reported a position in Xeris Biopharma Holdings in Q4 2022 and held it in 1 quarter.
  • Tri Locum Partners's Xeris Biopharma Holdings position peaked at $49K in Q4 2022.
  • 92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.